LEAMINGTON, Ontario, and CANTANHEDE, Portugal, Aug. 17, 2022 – PRESS RELEASE – Tilray Brands Inc., a leading global cannabis-lifestyle and consumer packaged goods company, announced that its medical cannabis division, Tilray Medical, has received approval to commercialize its Tilray branded medical cannabis products in Poland expanding its product offering and distribution across pharmacies in Europe.

Denise Faltischek, Tilray’s chief strategy officer and head of International Business, said, “I’m extremely proud of our team in Europe for once again expanding our approved authorization for Tilray Medical products across Europe. Tilray will continue to advocate for reasonable patient access to reliable and high-quality medical cannabis in Europe and countries around the world.”

Tilray Medical is a leading international provider of EU-GMP certified medical cannabis products in 21 countries with a comprehensive portfolio of trusted and reliable THC and CBD products, each with a unique profile of cannabinoids and terpenes, that have been selected to ensure patients can receive both the highest product quality as well as consistency when it comes to supply of their medicinal cannabis products.

In Poland, Tilray Medical has established multiple partnerships with pharmaceutical companies to distribute both Tilray branded and unbranded medical cannabis products. Patients may obtain prescriptions for medical cannabis in Poland through their preferred medical doctor.

]]>